Perimenopause vs. Menopause: Lab Values and what they mean

The clinical mistake we see most often in women's hormone care isn't overtreatment or undertreatment — it's mistreatment. A woman in early perimenopause gets handed the same protocol as a woman five years post-menopause, and the results are predictable: breakthrough bleeding, mood swings, or symptoms that never quite resolve.

The two phases are not the same disease. They're not even the same physiology. And the lab values, if you know what to look for, will tell you which one you're in.

What perimenopause actually looks like on a panel — in plain English

Perimenopause is the transition. The ovaries aren't done — they're erratic. Follicles are being recruited in irregular waves, some cycles ovulate, some don't, and the hormonal output looks less like a decline and more like a signal jammer.

On a single blood draw, a perimenopausal woman can show:

• FSH: anywhere from 10 to 40 mIU/mL, sometimes higher, sometimes back in the premenopausal range within weeks
• Estradiol: wildly variable — often higher than in her 20s during follicular surges (150–400 pg/mL), then crashing to 20 pg/mL days later
• Progesterone: frequently low in the luteal phase (<5 ng/mL when it should be 10–20), because anovulatory cycles produce no corpus luteum
• AMH: low, usually <1.0 ng/mL, trending toward undetectable

The defining feature is variability, not deficiency. This is why a single FSH draw is diagnostically weak in perimenopause — the Stages of Reproductive Aging Workshop (STRAW+10) criteria explicitly rely on menstrual cycle changes over lab values in this window.

If your cycles have changed length by seven or more days, you are almost certainly in early perimenopause — regardless of what a one-time FSH says.

What menopause looks like on a panel — the flat line

Menopause is defined clinically as 12 consecutive months without a period. Biochemically, it's a settled state:

• FSH: consistently >30 mIU/mL, often 70–100+
• Estradiol: consistently <20 pg/mL, often <10
• Progesterone: undetectable or <0.5 ng/mL
• LH: elevated, usually 20–60 mIU/mL
• AMH: undetectable

The pattern is stable across repeat draws. That stability is diagnostically useful — a postmenopausal panel doesn't need to be re-run every three months to interpret. It also means treatment targets are clearer: you're replacing what's absent, not chasing what's oscillating.

Why the same symptom means different things in each phase

Hot flashes, sleep disruption, mood changes, and brain fog show up in both windows. But the mechanism differs.

In perimenopause, symptoms are often driven by rapid estradiol swings — the brain reacts more to the delta than the absolute number. A woman with an estradiol of 180 pg/mL can still flash if she was at 380 last week.

In menopause, symptoms are driven by sustained estradiol deficiency and its downstream effects on thermoregulation, sleep architecture, bone turnover, and vaginal tissue.

This is why simply "adding estrogen" to a perimenopausal woman can backfire. If her ovaries surge the following week, she's now stacked on top of a physiologic estradiol peak, and the symptoms she came in for (breast tenderness, migraine, heavy bleeding) get worse.

{callout: The clinical takeaway} Perimenopause is a problem of hormonal chaos and often progesterone insufficiency; menopause is a problem of hormonal absence. The treatment logic follows from that distinction.

What each phase actually calls for

Perimenopause

The most common early intervention is cyclic or continuous progesterone — usually oral micronized progesterone at bedtime — to address the luteal phase deficiency, stabilize sleep, and protect the endometrium from unopposed estrogen surges. Standard published dosing ranges from 100–200 mg nightly.

Estrogen is added when vasomotor symptoms or genitourinary symptoms are prominent, but the dose is typically lower and titrated cautiously because endogenous estradiol is still contributing unpredictably. Transdermal delivery is preferred in most guidelines (NAMS 2022 Position Statement) due to a more favorable clotting profile.

Contraception is still relevant here — perimenopausal women can and do conceive. HRT is not contraception.

Menopause

With the ovaries fully quiet, the framework shifts to replacement. Transdermal estradiol (patch, gel, or spray) at a dose that resolves symptoms, paired with continuous progesterone for anyone with a uterus. The Women's Health Initiative reanalyses and the 2022 NAMS position statement both support initiation within 10 years of menopause or before age 60 for the most favorable risk-benefit profile.

Testosterone is a separate conversation and worth having — the Global Consensus Position Statement on testosterone therapy in women (2019) supports its use for hypoactive sexual desire disorder in postmenopausal women, using formulations dosed to premenopausal physiologic ranges.

The labs worth having before starting HRT

Regardless of phase, the markers that meaningfully change a treatment plan are:

• FSH, LH, estradiol, progesterone — to place you on the STRAW+10 map
• TSH and free T4 — thyroid symptoms mimic and mask menopausal symptoms constantly
• Fasting glucose, HbA1c, and a lipid panel — cardiometabolic baseline before any hormone therapy
• Vitamin D, ferritin, B12 — three deficiencies that drive fatigue and mood symptoms independently
• CBC and CMP — baseline liver and kidney function
• Total and free testosterone, SHBG — if libido, energy, or muscle changes are part of the picture

A thorough workup would typically include these before a serious protocol, and if you choose to do bloodwork through us, this is the panel we start with. The point isn't to gate treatment behind a lab — it's that hormone therapy without context is guessing, and guessing is how women end up on the wrong protocol for three years.

What to expect from a well-matched protocol

In perimenopause, the first thing that usually shifts on progesterone is sleep — often within the first week or two. Cycle regularity and mood follow over 2–3 months. Estrogen additions, when appropriate, address hot flashes within days to weeks.

In menopause, transdermal estradiol typically reduces vasomotor symptoms by 70–90% within 4–12 weeks (per pooled data in the NAMS statement). Genitourinary symptoms respond to local vaginal estrogen faster than systemic therapy. Bone density benefits accrue over years, not months.

None of this is guaranteed, and individual response varies. But matched to the right phase, with the right labs behind it, HRT stops being a gamble and starts being a plan.

The bottom line

Perimenopause and menopause are different biochemical states that happen to share a symptom list. Reading the panel correctly — recognizing chaos versus absence, variability versus stability — is what turns generic hormone therapy into a protocol tuned to the phase you're actually living in.

If your cycles are changing but not gone, you're likely in perimenopause and progesterone is probably the first lever. If your cycles have been gone for a year or more, you're in menopause and the conversation is about replacement, timing, and route.

The labs won't tell you how you feel. But they will tell you which treatment logic applies — and that's the difference between a protocol that works and one that doesn't.

Editorial disclosure: This article is for informational purposes only and does not constitute medical advice. All treatments at DirectCare AI are prescribed by US-licensed clinicians based on individual medical evaluation. Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Always consult a US-licensed clinician before starting or changing any therapy.